covid_cell

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | July 15, 2020 | News story | Research and Development COVID-19, coronavirus, vaccines 

The coronavirus news this week focuses on therapeutics, with Gilead’s remdesivir reducing the risk of death in 62% of severe COVID-19 patients, while the rheumatoid arthritis drug tocilizumab reduces death rates in patients on ventilation.

In other news, Russia has become the first country to complete a COVID-19 vaccine trial on humans, according to the Russian News Agency, while scientists have warned that coronavirus could lead to a wave of brain damage in people who were infected with the virus.

1. Russia claims it has completed the first human trial for COVID-19 vaccinePublished on 13/07/20

Russia has become the first country to complete a COVID-19 vaccine trial on humans, according to the Russian News Agency.

2. Itolizumab “significantly reduced mortality” in hospitalised COVID-19 patients with respiratory distress, secures emergency use authorisation in IndiaPublished 13/07/20

Itolizumab, a drug currently being developed by biotech firm Equillium for autoimmune and inflammatory disorders, “significantly reduced mortality” in hospitalised COVID-19 patients in an India-based clinical trial, it has emerged.

3. Remdesivir cuts death risk by 62% in coronavirus patients, new study showsPublished on 13/07/20

Gilead’s remdesivir reduced the risk of death in 62% of severe COVID-19 patients, according to a new study.

4. Arthritis drug reduces COVID-19 deaths for patients on ventilatorsPublished on 14/07/20

The rheumatoid arthritis drug tocilizumab reduces death rates in coronavirus patients on ventilation, according to new studies.

5. Scientists warn of brain damage linked to COVID-19Published on 10/07/20

COVID-19 could lead to a wave of brain damage in people who were infected with the virus.

Conor Kavanagh

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

CureVac and GSK begin phase 1 trial for mRNA flu vaccine candidates

CureVac and GSK have announced that the first patient in the phase 1 section of …

moderna_norwood_plant

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Latest content